Myosite nécrosante immunomédiée à statines : un diagnostic à évoquer
Résumé
Texte intégral :
PDFRéférences
Bergua C, Chiavelli H, Simon JP et al.Immune mediated necrotizing myopathy. Z. Rheumatol. 2016; 75(2), 151-62.Camillo Ribi Nouveaux auto-anticorps dans les myopathies inflammatoires et la sclérose systémique Rev Med Suisse 2015 ; 11: 25-9 3. Bergua C, Chiavelli H, Allenbach Y, Chritophe L A-D and al. In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy Annales of Rheumatic diseases, Ann Rheum Dis. 2019; 78(1): 131-1394.Fauchais AL, Iba Ba J, Maurage P, Kyndt X, Bataille D, Hachulla E, Parent D, Queyrel V et coll. Polymyosites induites ou associées aux traitements hypolipémiants ? À propos de cinq cas. La revue de médecine interne 2004 ; 25(4) : 294–298 5.Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-Mediated Necrotizing Myopathy Curr Rheumatol Rep. 2018; 20(4): 21 6.Margherita Milone, MD, PhD Diagnosis and Management of Immune-Mediated Myopathies Mayo Clin Proc 2017; 92(5): 826-8377.Mammen AL, Chung T, ChristopherStine L, Rosen P, Rosen A, Doering KR and Casciola-Rosen LA. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011; 63, 713–7218.Troyanov Y et al. Atorvastatin induced necrotizing autoimmune myositis, an emerging dominant entity in patients with autoimmune myositis presenting with pure polymyositis phenotype. Medicine 2017; 96(3): e56949.Allenbach Y, Drouot L, Rigolet A, Charuel JL, Jouen F, Romero NB, Maisonobe T, Dubourg O, Behin A, Laforet P et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore) 2014; 93: 150–15710. Suzuki S, Nishikawa A, Kuwana M, Nishimura H, Watanabe Y, Nakahara J, Hayashi YK, Suzuki N and Nishino I. Inflammatory myopathy with antisignal recognition particle antibodies: case series of 100 patients. Orphanet J. Rare Dis. 2015; 10. 6111. Guillemotonia MJ, De Witte S, Dauba J. Dermatomyosite secondaire à l’administration de trastuzumab (Herceptin®). J Pharm Clin 2013 ; 32(1) : 57-61 12. Tiniakou E, Pinal-Fernandez I, Lloyd TE et al. More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutarylcoenzyme. A reductase-associated autoimmune myopathy. Rheumatology. 2017; 56: 787-79413. Schmidt J. Current classification and management of inflammatory myopathies. J Neuromuscul Dis. 2018;5: 109-129 14. Meyer A, Troyanov Y, Drouin J et al.Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients. Arthritis Res Ther. 2020; 22(1): 515. Mammen AL, Tiniakou E. Intravenous immune globulin for statin-triggered autoimmune myopathy. N Engl J Med. 2015, 373: 1680-1682
Renvois
- Il n'y a présentement aucun renvoi.